SSKN

STRATA Skin Sciences Announces Renewal of Exclusive Distribution Agreements in China and Japan

Retrieved on: 
Tuesday, April 9, 2024
SSKN, Dermatology, Marketing, Pharmaceutical industry

HORSHAM, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the renewal of two distinct distribution agreements in international territories – one with the current exclusive distributor in China and a second with the current exclusive distributor in Japan.

Key Points: 
  • HORSHAM, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the renewal of two distinct distribution agreements in international territories – one with the current exclusive distributor in China and a second with the current exclusive distributor in Japan.
  • Terms of each of the distribution agreements are for three years and carry minimum unit placements and/or purchases of the XTRAC and VTRAC devices.
  • “The renewal of these exclusive distribution agreements in China and Japan, when coupled with the renewal of the distribution agreement in South Korea announced in December 2023, brings improved visibility to the international segment of our business,” stated Dr. Dolev Rafaeli, STRATA’s President and Chief Executive Officer.
  • We look forward to continued mutually beneficial relations with each and leveraging our installed base around the world, as service and parts sales are an important aspect of our international business.”

STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

Retrieved on: 
Wednesday, March 27, 2024
Growth, Webcast, Tax, International, Bank statement, Dermatology, DTC, Acne, Direct, Annual report, Report, Interest, Safety, SSKN, ID, Marketing, STRATA, Video game

Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.

Key Points: 
  • Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.
  • Equipment revenues were $3.1 million for the fourth quarter of 2023, as compared to $4.1 million for the fourth quarter of 2022.
  • Selling and marketing costs for the fourth quarter of 2023 were $2.8 million, as compared to $3.8 million for the fourth quarter of 2022.
  • Other expenses for the fourth quarter of 2023 were $0.4 million, compared to $0.2 million for the fourth quarter of 2022.

STRATA Skin Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024

Retrieved on: 
Wednesday, March 13, 2024
SSKN, Marketing

HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it plans to release its fourth quarter and full-year 2023 financial results on Wednesday, March 27, 2024.

Key Points: 
  • HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it plans to release its fourth quarter and full-year 2023 financial results on Wednesday, March 27, 2024.
  • Management will hold a conference call to review the financial results and provide a corporate update at 4:30 PM ET on the same day.

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

Retrieved on: 
Thursday, March 7, 2024
Lichen planus, Light therapy, Assistant, Vitiligo, Marketing, Cutaneous T-cell lymphoma, Quality of life, Senate, Atopic dermatitis, Skin, CTCL, Mycosis fungoides, CPT, Human, Light, Alopecia areata, Patient, STRATA, SSKN, Insurance, Pharmaceutical industry

The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

Key Points: 
  • The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.
  • “Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA.
  • Over the past two months, as part of this advocacy initiative STRATA has sent over 1,000 legislative support letters to congressional and senate delegates on behalf of its patients.
  • Phototherapy has been the cornerstone of therapy for decades and remains an indispensable part of current therapy.

STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial

Retrieved on: 
Monday, February 26, 2024
Marketing, Partnership, Amendment, SSKN

HORSHAM, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the successful amendment of its credit and security agreement with MidCap Financial Trust (“MidCap”) effective February 20, 2024.

Key Points: 
  • HORSHAM, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the successful amendment of its credit and security agreement with MidCap Financial Trust (“MidCap”) effective February 20, 2024.
  • This amendment, recognized as Amendment No.
  • 4 (“Amendment”), removes the minimum revenue requirements for 2023 and introduces future financial covenants.
  • Dolev Rafaeli, STRATA’s Vice Chairman and Chief Executive Officer, remarked, “This amendment signifies the strength of our partnership with MidCap Financial Trust and our lenders.

STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference   

Retrieved on: 
Monday, January 8, 2024
Marketing, FAAD, Cosmetic, Light, Needle, Acne, Edema, Patient, Safety, SSKN, Erythema

The poster highlights the safety and efficacy of one treatment session using STRATA’s TheraClear®X technology for cystic and papular acne reduction.

Key Points: 
  • The poster highlights the safety and efficacy of one treatment session using STRATA’s TheraClear®X technology for cystic and papular acne reduction.
  • Majority of lesions demonstrated ≥50% clearing by 1-2 weeks, exceeding the criteria of ≥30% reduction in lesion size at two follow-up visits.
  • At 1-2 weeks, the most frequently reported event was mild hyperpigmentation; erythema, edema, and flaking were observed in ≤10% of lesions.
  • “The TheraClear®X Photopneumatic acne system used with the additional needle insert is a very effective and safe treatment for both cystic and pustular acne lesions.

STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Retrieved on: 
Wednesday, January 3, 2024
Marketing, Notice, Calendar, SSKN, Auction

HORSHAM, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it has received a notification letter (“Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule.

Key Points: 
  • HORSHAM, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it has received a notification letter (“Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule.
  • As previously disclosed, on June 26, 2023, the Company received Notice from Nasdaq notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by failing to maintain a minimum closing bid price for its common stock on the Nasdaq Global Select Market of at least $1.00 per share for 30 consecutive business days.
  • The Company was given a period of 180 calendar days, or until December 26, 2023, to regain compliance with the minimum closing bid price requirement.
  • If at any time before June 24, 2024, the closing bid price of the Company’s ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed.

STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech

Retrieved on: 
Friday, December 29, 2023
Marketing, Growth, Partnership, SSKN, STRATA

HORSHAM, Pa., Dec. 29, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the expansion of a direct distribution agreement with Kosmo Meditech (“Kosmo”), which is now assigned to Kosmo's corporate parent, Cutech, Inc., effective as of January 1, 2024, for a combination of direct capital sales and direct recurring revenue sales in Korea.

Key Points: 
  • HORSHAM, Pa., Dec. 29, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the expansion of a direct distribution agreement with Kosmo Meditech (“Kosmo”), which is now assigned to Kosmo's corporate parent, Cutech, Inc., effective as of January 1, 2024, for a combination of direct capital sales and direct recurring revenue sales in Korea.
  • The key highlights of this amendment, which reinforce STRATA's commitment to innovation and customer satisfaction, include:
    Extended term through December 31, 2026, ensuring a prolonged and stable partnership
    Established defined annual and quarterly performance-based purchase requirements, including STRATA becoming sole provider of gas and consumables, securing a consistent demand for STRATA’s products, providing a reliable forecast for production and inventory management, and ensuring stronger top-line revenue
    “This agreement not only signifies the strength and growth of the partnership between STRATA and Kosmo but also reinforces STRATA's dedication to upholding the highest standards in product and service offerings for dermatological treatments worldwide,” stated Dr. Dolev Rafaeli, President and Chief Executive Officer of STRATA.
  • “Korea continues to present a significant opportunity for us, leveraging Kosmo’s extensive in-country distribution network.
  • This ongoing collaboration allows us to provide our customers with innovative therapeutic solutions while ensuring a framework for sustainable growth and market leadership.”

STRATA Skin Science Announces Strengthening of Leadership Team

Retrieved on: 
Monday, December 4, 2023
Marketing, Business, Research, Acquisition, Business administration, Electronics, Cornell University, Master of Business Administration, Knowledge, Engineering, STRATA, Growth, Publication, SSKN, Pleasure, Management

HORSHAM, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the promotion of Shmuel Gov to Chief Operating Officer. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth.

Key Points: 
  • His outstanding leadership, strategic insight, and continued commitment to our mission make him the ideal choice to drive our operational excellence.
  • Together, we will reach new heights and achieve success in our shared journey,” expressed Shmuel Gov, Chief Operating Officer of STRATA.
  • Additionally, Dr. Amandeep Kaur has rejoined STRATA and brings years of experience and background in business development, marketing, and technology.
  • Her close ties with the clinical and research community and her experience as a business development leader will help STRATA accomplish its near-term turn-around goals.”

STRATA Skin Sciences to Participate in the Benchmark 12th Annual Discovery One-on-One Investor Conference

Retrieved on: 
Friday, December 1, 2023
Marketing, Conference, SSKN

HORSHAM, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the company will be participating in the Benchmark 12th Annual Discovery One-on-One Investor Conference being held in New York City on December 7, 2023.

Key Points: 
  • HORSHAM, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the company will be participating in the Benchmark 12th Annual Discovery One-on-One Investor Conference being held in New York City on December 7, 2023.
  • Details for the event are as follows:
    For more information about the conference, please visit the website , or to schedule one-on-one meetings with management, please email [email protected].